
Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.
David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of pembrolizumab plus chemotherapy as a frontline treatment for patients with non–small cell lung cancer (NSCLC).
David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of pembrolizumab plus chemotherapy as a frontline treatment for patients with non—small cell lung cancer (NSCLC).





